论文部分内容阅读
随着表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)在临床的广泛应用,耐药问题逐渐浮现,成为新的研究热点。大多数表皮生长因子受体(EGFR)突变阳性的非小细胞肺癌(NSCLC)患者在初始治疗大约6~12个月之后将出现继发性耐药,从而导致EGFR-TKI治疗失效。一、EGFR-TKI耐药1.原发性耐药:肿瘤对首次进行TKI药物治疗未出现响应,在症状改善、疾病进展和延长生存期等方面未获得明显提高,即为原发性耐药。2.继发性耐药:多数EGFR突变患者在接受
With the widespread application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in clinical practice, drug resistance problems gradually emerge and become a new research hot spot. Most NSCLC patients with positive EGFR mutations will develop secondary resistance approximately 6 to 12 months after initial treatment, resulting in failure of EGFR-TKI therapy. First, EGFR-TKI resistance 1. Primary resistance: the tumor did not respond to the first TKI drug treatment, no improvement was seen in the improvement of symptoms, disease progression and prolongation of survival, which is the primary drug resistance . 2. Secondary drug resistance: Most patients with EGFR mutations are receiving